Bristol-Myers Squibb Company (BMY)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Bristol-Myers Squibb Company.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 65.30 $ — 100% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 0.6% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 29
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6.83 | 6.33 – 7.15 | 49,533 | 11.0% | 24 |
| 12/31/2027 | 6.47 | 5.84 – 7.32 | 47,812 | -5.3% | 26 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.04 | -95.90 | 12,342 | 7.50 | 0.60 | 4,439 | 4,061 |
| 2025: Q1 | 1.21 | – | 11,201 | -5.60 | 21.90 | 1,954 | 1,694 |
| 2025: Q2 | 0.64 | -22.40 | 12,269 | 0.60 | 10.70 | 3,917 | 3,556 |
| 2025: Q3 | 1.08 | 81.10 | 12,222 | 2.80 | 18.00 | 6,311 | 5,991 |
| 2025: Q4 | 0.53 | 1,405.40 | 12,502 | 1.30 | 8.70 | 1,974 | 1,604 |
| 2026: Q1 | 1.31 | 8.70 | 11,489 | 2.60 | 23.30 | 1,104 | 757 |
| 2026: Q2 | 1.62 | 153.10 | 12,973 | 5.70 | 25.60 | 3,393 | 3,088 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 19,427 | 5,179 | 4,457 | 2.65 | 3,058 | 16,177 | 33,707 |
| 2017 | 20,776 | 5,239 | 1,007 | 0.61 | 5,275 | 11,741 | 33,551 |
| 2018 | 22,561 | 6,394 | 4,920 | 3.01 | 7,066 | 14,031 | 34,986 |
| 2019 | 26,145 | 6,439 | 3,439 | 2.01 | 8,067 | 51,598 | 129,944 |
| 2020 | 42,518 | 4,492 | -8,995 | -3.98 | 14,052 | 37,822 | 118,481 |
| 2021 | 46,385 | 9,540 | 6,994 | 3.12 | 16,207 | 35,946 | 109,314 |
| 2022 | 46,159 | 9,271 | 6,327 | 2.95 | 13,066 | 31,061 | 96,820 |
| 2023 | 45,006 | 8,472 | 8,025 | 3.86 | 13,860 | 29,430 | 95,159 |
| 2024 | 48,300 | 9,658 | -8,948 | -4.41 | 15,190 | 16,335 | 92,603 |
| 2025 | 48,195 | 13,724 | 7,054 | 3.46 | 14,156 | 18,473 | 90,038 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, fertigt, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Es bietet Produkte für Onkologie, Hämatologie, Immunologie, Herz-Kreislauf und Neurowissenschaft an.
| Employees | 32,500 |
|---|---|
| Headquarters | Princeton, NJ |
| Address | Route 206 & Province Line Road, 08543 Princeton, United States |
| Phone | 609 252 4621 |
| Website | bms.com |
| IPO Date | 1. Jan 1972 |
| ISIN | US1101221083 |
| Stock Split | 1000000:951777 on 08/07/2001 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Christopher S. Boerner Ph.D. | CEO & Chairman | 1971 |
| David V. Elkins | Executive VP & CFO | 1968 |
| Greg Meyers | Executive VP and Chief Digital & Technology Officer | 1973 |
| Adam Lenkowsky | Executive VP & Chief Commercialization Officer | 1972 |
| Cristian Massacesi M.D. | Executive VP, Chief Medical Officer & Head of Development | 1969 |
| Karin Shanahan | Executive VP, Chief Supply Chain & Operations Officer | 1965 |
| Charles E. Triano | SVP & Head of Investor Relations | – |
| Cari Gallman | Executive VP, General Counsel & Chief Policy Officer | 1980 |
| Ahn Amanda Poole | Executive VP & Chief People Officer | 1975 |
| Joseph J. Eiden Jr. | Head of Medical Affairs | 1949 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.